Article · SwissTechNova

SwissTechNova and Space Systems Innovation Platform SSIP will work together


By SwissTechNovaAugust 25, 20265 min read

Short answer: SwissTechNova has formalised a partnership with the Space Systems Innovation Platform (SSIP), an organisation building infrastructure and industry connections around in-space manufacturing and space-enabled research. The collaboration links SwissTechNova's engineering, project management and qualification expertise to a fast-growing sector that Morgan Stanley expects to exceed $1 trillion by 2040, with early opportunities already visible in pharmaceuticals, materials science and advanced manufacturing.

What is the Space Systems Innovation Platform (SSIP)?

The Space Systems Innovation Platform, known as SSIP, positions itself as a connective hub between space agencies, commercial launch and orbital infrastructure providers, research institutions and industrial partners who want to bring terrestrial products and processes into microgravity. Rather than building rockets itself, SSIP's role is to lower the barriers for organisations that want to run experiments, pilot manufacturing processes, or validate new materials in orbit — matching them with the right facilities, funding pathways and technical partners. This "platform" approach mirrors what is happening across the wider space economy: as launch costs fall and orbital access becomes more routine, the bottleneck shifts from getting to space to knowing how to design, qualify and scale a project once you're there.

Why SwissTechNova and SSIP are working together

SwissTechNova was built on the idea that ambitious, technically demanding projects need two things at once: architectural and engineering imagination, and disciplined project execution. That combination is exactly what translates across from terrestrial engineering projects to space-enabled ventures. In-space manufacturing, orbital laboratories and payload qualification programs face the same fundamental challenges as any large industrial build: feasibility analysis, risk management, budget control, and rigorous validation before anything goes into operation.

Through this partnership, SwissTechNova brings its experience in full-cycle project management, portfolio and risk management, and construction qualification and validation (CQV) to organisations working with SSIP on ground infrastructure, test facilities and industrial-scale applications of space-derived processes. SSIP, in turn, gives SwissTechNova and its clients a direct line into the network, expertise and opportunities that define this emerging industry.

Why the space economy matters now

The numbers explain why this is more than a symbolic partnership. Morgan Stanley projects the overall space economy will exceed $1 trillion by 2040, and in-space manufacturing alone has already reached a market value of over $800 million globally, fuelled by both commercial investment and government funding. These are not distant, speculative figures — they reflect real programs already running today, many of them built around the unique physical conditions available only in microgravity.

Space-enabled pharmaceutical development alone is projected to generate between $2.8 billion and $4.2 billion in future revenues.

Industry market projections cited by SwissTechNova and SSIP

Microgravity: a genuine industrial advantage

The reason pharmaceuticals and advanced materials are early leaders in this space is physical, not speculative. On Earth, gravity-driven convection and sedimentation limit how proteins and crystals form. In microgravity, that interference disappears, allowing proteins to form larger, purer, and more uniform 3D crystals than is possible in any terrestrial lab. This matters enormously for drug development, where crystal quality directly affects the stability, purity and effectiveness of a formulation.

This isn't theoretical. Merck used International Space Station experiments to reformulate the cancer drug Keytruda into a stable injectable version — work that secured FDA approval and demonstrated, in practical terms, that microgravity research can produce outcomes that reach real patients. It's a clear example of how orbital infrastructure can feed directly back into industries with strict engineering, safety and regulatory standards — the same discipline SwissTechNova applies to its own qualification and validation work on Earth.

Industries that stand to benefit

While pharmaceuticals currently lead the headlines, the SwissTechNova–SSIP partnership is designed with a broader set of sectors in mind:

  • Pharmaceuticals and biotech — protein crystallisation, drug reformulation and stability testing benefit directly from microgravity conditions.
  • Advanced materials and manufacturing — fibre optics, semiconductors and alloys can be produced with fewer defects when gravity-driven imperfections are removed.
  • Industrial infrastructure and facilities — ground stations, cleanrooms, test benches and qualification facilities require the same rigorous project delivery SwissTechNova applies to complex architecture and engineering projects.
  • Investment and portfolio strategy — organisations evaluating early positions in the space economy need structured risk and portfolio management approaches, not just technical enthusiasm.

Key takeaways

  • SwissTechNova and SSIP have formalised a partnership connecting Swiss engineering and project delivery expertise with the space innovation sector.
  • The overall space economy is projected by Morgan Stanley to exceed $1 trillion by 2040, with in-space manufacturing already valued at over $800 million globally.
  • Space-enabled pharmaceutical development is projected to generate $2.8–4.2 billion in future revenues, driven by advantages like purer protein crystal formation in microgravity.
  • Merck's ISS-based reformulation of Keytruda, which won FDA approval, shows these advantages are already translating into real, regulated products.
  • Pharmaceuticals, advanced materials, industrial infrastructure and investment strategy are the sectors best positioned to benefit from this collaboration.

Curious how SwissTechNova's engineering and project management expertise could support your next ambitious project — on Earth or beyond? Get in touch with our team to discuss your idea.

Market figures referenced from Morgan Stanley's space economy research; the Keytruda ISS reformulation case is documented in FDA approval records and NASA-affiliated microgravity research publications. See the NASA International Space Station program for background on microgravity research infrastructure.

Frequently asked questions

What is the Space Systems Innovation Platform (SSIP)?
SSIP is an organisation that connects space agencies, commercial space infrastructure providers, and industrial or research partners, helping them access facilities, funding and expertise to run projects and manufacturing processes in microgravity.
Why is SwissTechNova partnering with a space-focused organisation?
SwissTechNova's expertise in engineering, project management, risk management and qualification/validation applies directly to the demanding technical and infrastructure needs of space-enabled projects, making it a natural partner for SSIP's network.
Why does microgravity matter for industries like pharmaceuticals?
Without gravity-driven convection and sedimentation, proteins can form larger, purer and more uniform crystals in microgravity, which has already helped produce real outcomes such as Merck's FDA-approved reformulation of Keytruda using ISS research.
How big is the space economy expected to become?
Morgan Stanley estimates the overall space economy will exceed $1 trillion by 2040, with in-space manufacturing already valued at over $800 million globally today.